Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × DOXO-EMCH × Clear all
NCT02014844 2024-05-29

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

ImmunityBio, Inc.

Phase 2 Completed
28 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡